[Translation] A Phase III, double-blind, randomized, placebo-controlled, multicenter trial evaluating the efficacy and safety of AR1001 in subjects with early Alzheimer's disease for 52 weeks

评价AR1001与安慰剂相比在早期阿尔茨海默病受试者中的有效性

[Translation]

To evaluate the efficacy of AR1001 compared with placebo in subjects with early Alzheimer's disease

Start Date29 Nov 2024

Sponsor / Collaborator

Bonacia (Hefei) Pharmaceutical Technology Co., Ltd.

NCT05531526

/ RecruitingPhase 3

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants with Early Alzheimer's Disease (Polaris-AD)

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.

Start Date23 Dec 2022

Sponsor / Collaborator

ARIBIO Co., Ltd.

NCT03625622

/ CompletedPhase 2

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.

Start Date01 Apr 2019

Sponsor / Collaborator

ARIBIO Co., Ltd.

100 Clinical Results associated with Mirodenafil dihydrochloride

100 Translational Medicine associated with Mirodenafil dihydrochloride

100 Patents (Medical) associated with Mirodenafil dihydrochloride

4,959

Literatures (Medical) associated with Mirodenafil dihydrochloride

01 Jun 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Energy-efficient CO2 capture using novel low-viscosity water-lean aromatic amine solvent MBA/BDMA/EG/H2O: Performance, mechanism and thermodynamics

Author: Chi, Shudan ; Li, Wenrui ; Yang, Linjun ; Yu, Hang ; Hou, Dawei ; Wang, Xin ; Jin, Lijian ; Yang, Hangqi ; Kong, Sining ; Hou, Xueyan

To address the challenges of high regeneration energy and corrosion in traditional mixed amine absorbents, as well as the increased viscosity issues in water-lean absorbents post-saturation, this study introduces the co-solvent ethylene glycol (EG) to replace part of the water in the high stability N-methylbenzylamine (MBA) and N, N-dimethylbenzylamine (BDMA) systems, resulting in a novel water-lean aromatic amine solvent, MBA/BDMA/EG/H₂O, is proposed as an alternative solutionThe addition of the tertiary amine BDMA significantly enhanced the regeneration efficiency of the absorbent.When the mass ratio of MBA/BDMA/EG/H₂O is set at 1.5:1.5:3.5:3.5, the CO₂ loading reaches 0.36 mol/mol, while the viscosity is only 10.82 mPa·s at room temperatureThe CO₂ capture mechanism of this absorbent was elucidated using ¹³C NMR and quantum chem. calculationsInitially, CO₂ reacts with MBA to form MBACOO^-/MBAH⁺.Subsequently, MBA⁺COO^- undergoes deprotonation to produce MBAH⁺ and BDMAH⁺.As the concentration of free MBA decreases to a certain level, BDMA undergoes hydrolysis, resulting in the formation of HCO^-₃.In the later stages of absorption, some of the carbamate products convert to unstable alkyl carbonates by reaction with EG.Notably, the regeneration energy of MBEH is reduced by 21.1% (estimate), compared to 30% MEA aqueous solutionThe corrosion rate of 30% MEA (after absorption) on carbon steel is 3.6 times higher than that of MBEH (after absorption).Therefore, the proposed MBEH solution presents a promising absorbent with excellent desorption performance, low viscosity, reduced regeneration energy, and low corrosion rate.

01 May 2025·JOURNAL OF HAZARDOUS MATERIALS

Degradation of N-methylbenzylamine and N,N-dimethylbenzylamine in anaerobic biological reactors and formation of N-nitrosomethylbenzylamine and N-nitrosodimethylamine during subsequent chloramination

Article

Author: Chen, Guan-Fu ; Premarathne, Iresha ; Peng, Shih-Wen ; Tseng, Yu-Chun ; Su, Yu-Jih ; Chen, Wei-Hsiang

As water reuse demand increases, wastewater treatment plants must manage byproducts effectively while ensuring safety. The excessive use of benzalkonium chloride disinfectants can lead to the accumulation of benzylamines, such as N-methylbenzylamine (MBA) and N,N-dimethylbenzylamine (DMBA). Biological anaerobic treatment is becoming more popular due to concerns over energy consumption and carbon emissions. Our study examined the biodegradation of MBA and DMBA during anaerobic treatment and their effects on toxic byproduct formation during subsequent chloramination, as well as their impact on bioreactor performance, degradation pathways, and microbial communities. Our results showed that anaerobic bioreactors had minimal impact on overall treatment performance despite the presence of MBA and DMBA. MBA proved resistant to biodegradation, whereas DMBA underwent significant biodegradation. Notably, during chloramination, MBA effluent formed nitroso-MBA with a 1 % molar yield, whereas DMBA effluent had significant N-nitrosodimethylamine formation, with molar yields reaching 10 ± 1 % and 97 ± 7 % of the influent and residual DMBA concentrations. We observed significant differences in microbial communities between the DMBA reactor and the MBA and control reactors. Proposed degradation pathways and the involvement of specific microbial communities were detailed. These findings highlight the importance of thoroughly evaluating biologically treated effluent to manage the risks of toxic byproducts in water reuse.

01 May 2025·JOURNAL OF CATALYSIS

Exhaustive reduction of aromatic esters and carboxylic acids with a homogeneous cobalt catalyst

Author: Xu, Bao-Hua ; Zhang, Yan-Qiang ; Lin, Jin-Qing ; Sun, Rui ; Zhang, Zi-Heng ; Jiang, Yuan-Yuan

A one-step procedure to exhaustively reduce aromatic esters and carboxylic acids to their corresponding tolyl derivatives is a significant transformation in organic synthesis, which remains challenging in homogeneous catalysis.In this study, it's achieved by using the well-defined phosphinesulfonate chelated cobalt-based catalyst (Co(dppbsa)), along with NaBAr^F₄ as the basic additive and (MeO)₂MeSiH as the reductant.Particularly, this cobalt catalysis proceeds through ether intermediates.Exptl. combined theor. results support it follows an outer-sphere ionic hydrosilylation mechanism and the in situ formed cationic siloxane species are involved in the rate-limiting hydride transfer.The same system also enables the catalytic deoxygenation of aliphatic esters, aliphatic acids, and amides but terminating at the corresponding ethers, alkanols and secondary amines, resp.These findings open up novel avenues for the catalytic application of phosphinesulfonate chelated complexes, potentially serving as the foundation for the exhaustive reduction of carboxylic skeletons with cobalt.

News (Medical) associated with Mirodenafil dihydrochloride

15 Oct 2024

·www.prnewswire.com

Neurophet-AriBio to develop 'Next-Gen Platform for Alzheimer's diagnosis'

- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease - Collaborates leveraging Neurophet's medical image analysis technology and AriBio's clinical trial data analysis expertise SEOUL, South Korea, Oct. 15, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its collaboration with AriBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, to develop next-generation platform for Alzheimer's diagnosis. Continue Reading Neurophet-AriBio to develop ‘Next-Gen Platform for Alzheimer's diagnosis’ The collaboration aims to develop a new Alzheimer's diagnostic platform by integrating Neurophet's brain image analysis technology using MRI (magnetic resonance imaging) with fluid biomarker data from AriBio's global Phase 3 clinical trial for early Alzheimer's disease. AriBio's platform team with clinical trial data analytics capabilities will collaborate with Neurophet's AI team on developing this advanced diagnostic platform. The conventional method to diagnosing Alzheimer's disease typically involves amyloid-PET (positron emission tomography) scan or CSF (cerebrospinal fluid) test to detect cortical amyloid beta deposition and confirm the presence of Alzheimer's. However, amyloid-PET scans are relatively expensive, and the CSF test involves a lumbar puncture, where a long needle is inserted between the vertebrae to drain fluid, which causes pain and requires time for recovery. These limitations result in lower medical accessibility for patients. To address these challenges, Neurophet and AriBio are developing a new diagnostic platform. The plan is to create a platform that can predict the risk of amyloid beta protein positivity early by conducting MRI analysis and blood-based biomarker tests before amyloid-PET scans. This approach aims to reduce unnecessary amyloid-PET scans and actively utilize a more accessible Alzheimer's disease testing method. "By participating in AriBio's global Phase 3 clinical trial of AR1001, a broad range of medical data will be obtained to achieve meaningful research outcomes in various fields." said Jake Junkil Been, CEO of Neurophet. "If this platform is successfully developed, it could significantly reduce medical costs associated with dementia diagnosis and treatment, while also improving patient convenience." Jai Jun Choung, CEO of AriBio stated, "AriBio is working on a safe and easy-to-take oral tablet to ensure accessibility and convenience for Alzheimer's disease patients and their families, and we hope to further enhance diagnostic accessibility through our collaboration with Neurophet." Neurophet has entered into an agreement with AriBio to participate in the global phase 3 clinical trial of AR1001, an oral treatment for Alzheimer's disease. Neurophet plays a key role in identifying eligible patients for the trial and assessing the treatment effect of AR1001 using its brain imaging analysis technology. In addition, the two companies are conducting joint research and business development by utilizing the medical image, blood, and CSF data obtained from the large-scale, multinational AR1001 clinical trials. About Neurophet Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", brain PET image analysis (PET tracer deposition) software "Neurophet SCALE PET", brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB". Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology. SOURCE Neurophet WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

04 Oct 2024

·www.mobihealthnews.com

Indian mental health app Lissun takes on AI with $3M and more briefs

Mental health app Lissun bags $3M for AI integration Mental health platform Lissun in India has scored $2.5 million in a pre-Series A funding round led by RPSG Capital Ventures. With its fresh funds, the startup plans to integrate AI into its suite of digital mental health solutions which target corporates, schools, and families of children with neurodevelopmental conditions. The new funds will also go to expanding their services and growing their team. Proceeds from this new investing round bring its total investment to $5 million. Lissun last raised over $1 million in seed funding in September of the previous year. Asan Medical Center first to prescribe locally-approved vision loss DTx Asan Medical Center (AMC), one of South Korea's biggest hospitals, has started prescribing a Korean-made digital therapeutic for visual impairment due to stroke. The mobile-based application Vivid Brain provides training through virtual reality to enhance a user's response to visual stimuli. AMC officially prescribed the solution in September, five months after it was cleared by the Korean government – the third for a local DTx. AMC professor Kang Dong-hwa, who developed Vivid Brain with Nunaps (a local company he founded), now plans to expand their DTx to hospitals locally and abroad. Neurophet's latest collab to predict Alzheimer's risk Korean medical imaging AI company Neurophet has announced a new partnership that will develop a new Alzheimer's disease diagnosis platform. In a statement, the company said it will collaborate with local biotechnology firm Aribio, which develops treatment for neurodegenerative diseases. They intend to integrate Neurophet's MRI-based image analysis software with Aribio's blood-based Alzheimer's diagnostic test to detect early people with Alzheimer's-positive amyloid beta protein deposits in their brains. Their solution, according to a press release, seeks to make Alzheimer's testing more accessible, reducing repeat testing with the costly amyloid-PET imaging. Neurophet and Aribio's collaboration builds on their existing work in the global clinical trial of Aribio's oral Alzheimer's treatment AR1001, phase 3. In July, Neurophet unveiled the Neurophet AQUA AD, its latest Alzheimer's treatment prescription and monitoring software.

Drug Approval

30 Sep 2024

·www.globenewswire.com

Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a clinical trial site organization whose mission is to democratize clinical trials by providing full-service support to trial investigators in community settings, announced two community practices that are part of the Adaptive Research network have begun patient enrollment and randomization in AriBio’s Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (POLARIS-AD). Noor Sachdev, MD and Perminder Bhatia, MD will serve as investigators with regulatory, finance, and clinical support for all study-related activities provided by Adaptive Research. “Studies such as this—which require participants to have signs and symptoms associated with the early stage of Alzheimer’s, such as some memory, planning, and organizational issues, and have a care partner who can accompany them to study visits—demonstrate the value of including community sites,” said Deepak Behera, MD, President and Chief Executive Officer of Adaptive Research. “Travel time to academic settings can contribute to inequalities in Alzheimer's disease clinical trial enrollment due to age, geography, and ethnicity. To recruit study populations that reflect the treatment population and make it easier for them to stay in the study, Sponsors need sites closer to patients that can produce quality data. In fact, community sites tend to know the patient population better resulting in a lower screen fail rate and better patient retainment compared to other settings.” “As we engage with interested investigators and sites across the world who are committed to making a difference in the treatment of patients with Alzheimer’s disease, we are pleased to have access to these community physicians who are on the front lines of patient care and often the first to see patients with early AD. These sites are paramount to running successful trials and providing access to diverse populations,” said James Rock, Chief Clinical Officer for AriBio. AriBio previously completed a Phase 2 study (NCT03625622) with AR1001 in a mild to moderate AD population in the US. AriBio is expected to enroll 1150 participants in this global Phase 3 clinical trial to evaluate the therapeutic potential of AR1001 in the treatment of early Alzheimer’s disease. About AR1001 About AR1001-ADP3-US01 AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov (https://clinicaltrials.gov/study/NCT05531526). About Adaptive Research Founded in 2020, Adaptive Research Inc. is revolutionizing the landscape of clinical trials. By offering full-service support to trial investigators, Adaptive Research connects Sponsors of potential life-saving investigational agents and medical devices with community physicians and their patients nationwide. Adaptive Research’s expert team functions as a virtual clinical trials office, managing administrative and regulatory responsibilities, and enabling physicians to focus on their paramount task: providing exceptional clinical judgement and care. For additional information, visit https://adaptiveresearch.com. About AriBio AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. Contacts:Inquiriesyour.partner@adaptiveresearch.com

Phase 2Phase 3

100 Deals associated with Mirodenafil dihydrochloride

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	China	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	Czechia	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	Denmark	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	France	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	Germany	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	Italy	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	Netherlands	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	Poland	ARIBIO Co., Ltd.	23 Dec 2022
Alzheimer Disease	Phase 3	Spain	ARIBIO Co., Ltd.	23 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03625622 (BusinessWire) Manual	Phase 2	Alzheimer Disease	210	AR1001 10 mg	xylnotvnoq(uuinmtqril) = hatxxocwop artvpymzry (ukmiqgtnrh )	Positive	04 Nov 2021
				AR1001 30 mg	aqosjcejtj(pdatlnzzzv) = pthrselnwl dlgbxyeuqy (snylbtdywd ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Mirodenafil dihydrochloride

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation